GC
XPH icon

Guggenheim Capital’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Guggenheim Capital’s Portfolio XPH Stock Details XPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-35,278
Closed -$1.24M – 3198
2013
Q2 		$1.24M Buy
+35,278
New +$1.19M 0.01% 1872

Other funds holding XPH

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
EC
Estate Counselors Thiensville, Wisconsin $1.16B AUM 21.97% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Guggenheim Capital's XPH Position: Q3 2013 in Review

Guggenheim Capital sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q3 2013, closing a stake of 35,278 shares — an estimated $1.24M sold.

Guggenheim Capital first reported a position in XPH in Q2 2013 and held it in 1 quarter. The position peaked at $1.24M in Q2 2013. 55 funds tracked by Wall St. Rank hold XPH as of Q3 2013.

  • Guggenheim Capital reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q3 2013 after selling out during the quarter.
  • Guggenheim Capital sold 35,278 State Street SPDR S&P Pharmaceuticals ETF shares in Q3 2013, an estimated $1.24M.
  • Guggenheim Capital first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2013 and held it in 1 quarter.
  • Guggenheim Capital's State Street SPDR S&P Pharmaceuticals ETF position peaked at $1.24M in Q2 2013.
  • 55 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2013.

Based on Guggenheim Capital's 13F filing for Q3 2013, filed 14 Nov 2013.